Resource impact statement
No significant resource impact is anticipated
NICE has recommended brigatinib as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) that has not been previously treated with an ALK inhibitor in adults.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population).
This is because the technology is a further treatment option and the overall cost of treatment will be similar. People who have brigatinib as a first line treatment would not have brigatinib at second line, therefore the cost of this treatment is partly offset by a reduction in the use of brigatinib as a second line treatment.
Brigatinib has a discount that is commercial in confidence. For enquiries about the patient access scheme contact gb.commercial@takeda.com.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: